The therapeutic potential of the proteasome in leukaemia
โ Scribed by Scott Marshall McCloskey; Mary Frances McMullin; Brian Walker; Alexandra E Irvine
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 198 KB
- Volume
- 26
- Category
- Article
- ISSN
- 0278-0232
- DOI
- 10.1002/hon.848
No coin nor oath required. For personal study only.
โฆ Synopsis
Abstract
Many cellular processes converge on the proteasome, and its key regulatory role is increasingly being recognized. Proteasome inhibition allows the manipulation of many cellular pathways including apoptotic and cell cycle mechanisms. The proteasome inhibitor bortezomib has enhanced responses in newly diagnosed patients with myeloma and provides a new line of therapy in relapsed and refractory patients. Malignant cells are more sensitive to proteasome inhibition than normal haematopoietic cells. Proteasome inhibition enhances many conventional therapies and its role in leukaemia is promising. Copyright ยฉ 2008 John Wiley & Sons, Ltd.
๐ SIMILAR VOLUMES
## Abstract The ubiquitinโproteasome system (UPS) is the major proteolytic pathway that degrades intracellular proteins in a regulated manner. Deregulation of the UPS has been implicated in the pathogenesis of many neurodegenerative disorders like Alzheimer's disease, Parkinson's diseases, Huntingt
Venlafaxine is the ยฎrst available antidepressant of the structurally novel SNRI (serotonin noradrenaline-reuptake inhibitor) class of drugs. It resembles the tricyclics in its ability to inhibit presynaptic reuptake of both serotonin and noradrenaline to a clinically signiยฎcant degree. However, it d
## Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.